Investors Overview

Unlocking a New Paradigm in Cancer Therapeutics

We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Using our proprietary Spyglass platform, we identify targets essential for ecDNA functionality, then design and develop small molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets and prevent cancer cells from using ecDNA to grow, adapt, and become resistant to existing therapies.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

More Stock Info

Who We Are